更正：奥希替尼在伴有骨转移的表皮生长因子受体（EGFR）突变的IV期肺腺癌中的无效性：一例报告。
Correction: The Ineffectiveness of Osimertinib in Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Lung Adenocarcinoma With Bone Metastasis: A Case Report.
作者信息
Livingston Caitlyn H, Harper Benjamin, George Mathew
机构信息
Neuroscience, Texas A&M University, College Station, USA.
Medical Oncology, Calvary Mater, Newcastle, AUS.
出版信息
Cureus. 2024 Aug 9;16(8):c188. doi: 10.7759/cureus.c188. eCollection 2024 Aug.
Abstract
[This corrects the article DOI: 10.7759/cureus.66240.].
摘要
[本文更正了文章的数字对象标识符（DOI）：10.7759/cureus.66240。]
相似文献
1
Correction: The Ineffectiveness of Osimertinib in Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Lung Adenocarcinoma With Bone Metastasis: A Case Report.更正：奥希替尼在伴有骨转移的表皮生长因子受体（EGFR）突变的IV期肺腺癌中的无效性：一例报告。
Cureus. 2024 Aug 9;16(8):c188. doi: 10.7759/cureus.c188. eCollection 2024 Aug.
2
The Ineffectiveness of Osimertinib in Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Lung Adenocarcinoma With Bone Metastasis: A Case Report.奥希替尼在表皮生长因子受体（EGFR）突变的伴有骨转移的IV期肺腺癌中的无效性：一例报告
Cureus. 2024 Aug 5;16(8):e66240. doi: 10.7759/cureus.66240. eCollection 2024 Aug.
3
Efficacy of 3rd generation TKI in patients with EGFR mutation lung adenocarcinoma with bone metastases: A review of 3 case reports and literature.三代 TKI 在伴有骨转移的 EGFR 突变肺腺癌患者中的疗效：3 例病例报告及文献复习。
Medicine (Baltimore). 2023 Aug 25;102(34):e34545. doi: 10.1097/MD.0000000000034545.
4
Proximal Femoral Metastasis From Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma Mimicking Osteosarcoma on Magnetic Resonance Imaging.表皮生长因子受体突变型肺腺癌的股骨近端转移在磁共振成像上酷似骨肉瘤
World J Oncol. 2024 Aug;15(4):731-735. doi: 10.14740/wjon1888. Epub 2024 Jul 5.
5
De Novo mutation in Epidermal growth factor receptor (EGFR)-D761Y responding to third generation tyrosine kinase inhibitor Osimertinib: A case report.表皮生长因子受体（EGFR）-D761Y 新生突变对第三代酪氨酸激酶抑制剂奥希替尼的反应：一例报告。
Medicine (Baltimore). 2022 Jul 22;101(29):e29332. doi: 10.1097/MD.0000000000029332.
6
A non-small cell lung cancer (NSCLC) patient harboring a rare epidermal growth factor receptor (EGFR) L858R/V843I mutation complex benefited from osimertinib: a case report.一位携带有罕见表皮生长因子受体（EGFR）L858R/V843I 突变复合物的非小细胞肺癌（NSCLC）患者从奥希替尼治疗中获益：一例报告。
Ann Palliat Med. 2022 Mar;11(3):1121-1125. doi: 10.21037/apm-21-2653.
7
Poor effect of osimertinib on EGFR exon 20 insertion-positive lung adenocarcinoma: A case report.奥希替尼对表皮生长因子受体第20外显子插入阳性肺腺癌疗效不佳：一例报告
Medicine (Baltimore). 2020 Oct 16;99(42):e22628. doi: 10.1097/MD.0000000000022628.
8
Analysis of lung adenocarcinoma with bone metastasis: a case report.肺腺癌伴骨转移的分析：一例报告
Transl Lung Cancer Res. 2020 Apr;9(2):389-392. doi: 10.21037/tlcr.2020.03.11.
9
Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With EGFR T790M-Mutated Non-Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor: West Japan Oncology Group 8715L Phase 2 Randomized Clinical Trial.奥希替尼联合贝伐珠单抗对比奥希替尼用于既往接受表皮生长因子受体酪氨酸激酶抑制剂治疗的 EGFR T790M 突变型非小细胞肺癌患者的疗效：西日本肿瘤学组 8715L 期随机临床试验。
JAMA Oncol. 2021 Mar 1;7(3):386-394. doi: 10.1001/jamaoncol.2020.6758.
10
Long-term response to osimertinib in elderly patients with lung adenocarcinoma harbouring de novo T790M: a case report and literature review.携带原发性T790M的老年肺腺癌患者对奥希替尼的长期反应：病例报告及文献综述
Respirol Case Rep. 2021 May 4;9(6):e00759. doi: 10.1002/rcr2.759. eCollection 2021 Jun.
Zotero 插件